SCHEMBL660369

SCHEMBL660369

Clc1nccc2ccsc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.48
MKNK1 Q9BUB5 1/20 0.48
MKNK2 Q9HBH9 1/20 0.48
ADORA2A P29274 8/20 0.43
ADORA1 P30542 8/20 0.43
CYP2A6 P11509 1/20 0.38
DYRK1A Q13627 1/20 0.36
ADORA3 P0DMS8 4/20 0.33
ADORA2B P29275 4/20 0.33
MAPT P10636 3/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 1/20 0.33
APEX1 P27695 1/20 0.33
MAPK1 P28482 1/20 0.33
PMP22 Q01453 1/20 0.33
KMT2A Q03164 2/20 0.33
SPR P35270 1/20 0.33
NPC1 O15118 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HSP90AA1 P07900 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377266 1.00 AXL (0.48) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL21243904 0.75 AXL (0.42) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL30656585 0.75 AXL (0.42) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL32691515 0.74 SPR (0.36) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL22323360 0.74 SPR (0.36) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL15391120 0.74 HSP90AA1 (0.36) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL6455853 0.74 HSP90AA1 (0.44) ADORA2AADORA1CYP2A6DYRK1AHSP90AA1
SCHEMBL368657 0.74 CYP2A6 (0.42) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL10479927 0.74 ADORA2A (0.34) AXLMKNK1MKNK2ADORA2AADORA1
SCHEMBL369616 0.74 CYP2A6 (0.47) ADORA2AADORA1CYP2A6SPRHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743175-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Aconcagua Bio, Inc. (US) 2026-05-20 EP disclosed
EP-4743174-A1 MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY Aconcagua Bio, Inc. (US) 2026-05-20 EP disclosed
EP-4739671-A1 NEW COMPOUNDS Aston University (GB) 2026-05-13 EP disclosed
EP-3909964-B1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO LTD (KR) 2025-10-08 EP disclosed
EP-4536356-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS Xenon Pharmaceuticals Inc. (CA) 2025-04-16 EP disclosed
US-20250092054-A1 FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS FMC CORPORATION 2025-03-20 US disclosed
US-20250066401-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2025-02-27 US disclosed
US-20250051355-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO, INC. 2025-02-13 US disclosed
US-20250042916-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO, INC. 2025-02-06 US disclosed
WO-2025015269-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO, INC. (US) 2025-01-16 WO disclosed
US-5321021-A Tricyclic pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 1994-06-14 US disclosed
EP-0318682-B1 TRICYCLIC THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1993-03-31 EP disclosed
CN-1016871-B Process for the preparation of bicyclic and tricyclic pyridine derivatives HOFFMANN LA ROCHE 7 CO F (CN) 1992-06-03 CN disclosed
US-5036066-A Muscle relaxants, anxiolytic agents, anticonvulsants HOFFMANN-LA ROCHE INC. (US) 1991-07-30 US disclosed
EP-0183994-B1 TRICYCLIC PYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1990-03-21 EP disclosed
US-4889848-A 4-OXO-4H-BENZO(A)QUINOLIZINES; MUSCLE RELAXANTS; SEDATIVES; ANTICONVULSANTS; ANXIOLYTIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1989-12-26 US disclosed
EP-0318682-A2 Tricyclic thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1989-06-07 EP disclosed
US-4735940-A Tricyclic pyridine derivatives and pharmaceutical compositions HOFFMANN-LA ROCHE INC. (US) 1988-04-05 US disclosed
CN-85108120-A The preparation of tricyclic pyridine derivative and application thereof 1986-11-05 CN disclosed
EP-0183994-A1 Tricyclic pyridone derivatives F. HOFFMANN-LA ROCHE AG (CH) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066401-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CYBA, C1S, CYC1 AXL 1983/4885MKNK1 2652/4885MKNK2 3006/4885
US-20250092054-A1 FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS PRF1, ACHE, C5 AXL 1915/4885MKNK1 2108/4885MKNK2 2231/4885
US-20250042916-A1 COMPOUNDS, COMPOSITIONS, AND METHODS IAPP, GIPR, GPR119 AXL 2377/4885MKNK1 2771/4885MKNK2 2547/4885
US-20250051355-A1 COMPOUNDS, COMPOSITIONS, AND METHODS IAPP, GIPR, GPR119 AXL 2377/4885MKNK1 2771/4885MKNK2 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.